This study is a Phase I/II trial using a novel bioengineered lenti viral vector to deliver a normal gene for human clotting factor VIII or factor IX into patients with hemophilia A or hemophilia B, to evaluate the safety, efficacy and pharmacokinetics of IV infusion of gene modified autoHST in patients.